|
|
Blood, 1 March 2007, Vol. 109, No. 5, pp. 2106-2111.
Prepublished online as a Blood First Edition Paper on October 26, 2006; DOI 10.1182/blood-2006-09-047712.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Shmuel Yaccoby1,
Wen Ling1,
Fenghuang Zhan1,
Ronald Walker1,
Bart Barlogie1, and
John D. Shaughnessy, Jr1
1 Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock
Dickkopf-1 (DKK1), a soluble inhibitor of Wnt signaling secreted by multiple myeloma (MM) cells contributes to osteolytic bone disease by inhibiting the differentiation of osteoblasts. In this study, we tested the effect of anti-DKK1 therapy on bone metabolism and tumor growth in a SCID-rab system. SCID-rab mice were engrafted with primary MM cells expressing varying levels of DKK1 from 11 patients and treated with control and DKK1-neutralizing antibodies for 4 to 6 weeks. Whereas bone mineral density (BMD) of the implanted myelomatous bone in control mice was reduced during the experimental period, the BMD in mice treated with anti-DKK1 increased from pretreatment levels (P < .001). Histologic examination revealed that myelomatous bones of anti-DKK1–treated mice had increased numbers of osteocalcin-expressing osteoblasts and reduced number of multinucleated TRAP-expressing osteoclasts. The bone anabolic effect of anti-DKK1 was associated with reduced MM burden (P < .04). Anti-DKK1 also significantly increased BMD of the implanted bone and murine femur in nonmyelomatous SCID-rab mice, suggesting that DKK1 is physiologically an important regulator of bone remodeling in adults. We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Advances in myeloma therapy: breaking the cycle
- Carl Gregory
Blood 2007 109: 1798.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. M. Edwards
Wnt signaling: bone's defense against myeloma
Blood,
July 15, 2008;
112(2):
216 - 217.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Blood,
July 15, 2008;
112(2):
374 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gregory
MM-induced osteolysis: partners in crime
Blood,
July 1, 2008;
112(1):
3 - 4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
Blood,
July 1, 2008;
112(1):
196 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Li, A. Pennisi, and S. Yaccoby
Role of decorin in the antimyeloma effects of osteoblasts
Blood,
July 1, 2008;
112(1):
159 - 168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-A. Kim, M. Wagle, K. Tran, X. Zhan, M. A. Dixon, S. Liu, D. Gros, W. Korver, S. Yonkovich, N. Tomasevic, et al.
R-Spondin Family Members Regulate the Wnt Pathway by a Common Mechanism
Mol. Biol. Cell,
June 1, 2008;
19(6):
2588 - 2596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-S. Wang, J.-Y. Ko, D.-W. Yeh, H.-C. Ke, and H.-L. Wu
Modulation of Dickkopf-1 Attenuates Glucocorticoid Induction of Osteoblast Apoptosis, Adipocytic Differentiation, and Bone Mass Loss
Endocrinology,
April 1, 2008;
149(4):
1793 - 1801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Edwards, J. R. Edwards, S. T. Lwin, J. Esparza, B. O. Oyajobi, B. McCluskey, S. Munoz, B. Grubbs, and G. R. Mundy
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
Blood,
March 1, 2008;
111(5):
2833 - 2842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Martin and K. W. Ng
New Agents for the Treatment of Osteoporosis
IBMS BoneKEy,
November 1, 2007;
4(11):
287 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Qian, J. Xie, S. Hong, J. Yang, L. Zhang, X. Han, M. Wang, F. Zhan, J. D. Shaughnessy Jr, J. Epstein, et al.
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
Blood,
September 1, 2007;
110(5):
1587 - 1594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, G. Donofrio, S. Bonomini, R. Sala, M. Mangoni, and V. Rizzoli
Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment
Cancer Res.,
August 15, 2007;
67(16):
7665 - 7674.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Colla, F. Zhan, W. Xiong, X. Wu, H. Xu, O. Stephens, S. Yaccoby, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
Blood,
May 15, 2007;
109(10):
4470 - 4477.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
